Abstract: Alzheimer’s disease (AD) and Alzheimer’s diseaserelated dementias (ADRD) represent a significant public health challenge, with projections indicating a substantial increase in affected individuals due to the aging global population. From the World Health Organization, AD/ADRD has affected more than 55 million individuals worldwide, with an additional 10 million cases diagnosed each year. According to the latest data from the Alzheimer’s Association, in the United States alone, AD/ADRD has already affected millions of individuals over the age of 65 years; this number is expected to double by 2060. In 2023, total payments in the US for AD/ ADRD individuals aged 65 and older amounted to $345 billion. The global cost of dementia care amounts to 1.3 trillion US dollars annually. Despite these impacts, AD/ADRD remains without a cure. The Food and Drug Administration-approved treatments have primarily addressed amyloidbeta (Aβ) buildup (aducanumab and lecanemab), cholinesterase inhibition (donepezil, rivastigmine, and galantamine), and glutamate regulation (memantine) or its combination with donepezil. Yet, none of these Food and Drug Administrationapproved treatments focus on targeting cerebral vascular pathological changes that are often associated with AD/ADRD (Fang et al., 2022).